Effect of iodopyracet on renal excretion of sulfamethizole in rabbits. 1990

K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.

To predict quantitatively drug interaction kinetics from the single-drug clearance studies, we examined the effect of iodopyracet (IOD) on sulfamethizole (SMZ) excretion in rabbits. Even though the decline of systemic IOD plasma concentration was linear, the renal clearance of SMZ decreased significantly in the presence of IOD. The results could be described by a perfusion model incorporated with the competitive inhibition for tubular secretion. For IOD with a high extraction ratio, it was suggested that a heavy load of the drug was supplied to the sites of secretion and caused the saturation of transport systems, even though the renal excretion kinetics were apparently linear in respect to the systemic circulation. These facts indicated that a linear relationship between the concentrations in the systemic circulation and at the sites of tubular secretion can not always be presumed. Consequently, SMZ-IOD interaction study stressed the importance of the drug concentrations at the sites of interaction for quantitative elucidation of drug-drug interactions.

UI MeSH Term Description Entries
D007468 Iodopyracet An ionic monomeric contrast medium that was formerly used for a variety of diagnostic procedures. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) Diodone,Cardiotrast,Diodrast,Kardiotrast
D007672 Kidney Cortex The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL. Cortex, Kidney
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013419 Sulfamethizole A sulfathiazole antibacterial agent. Rufol,Sulfamethizol FNA,Sulphamethizole,Thiosulfil,FNA, Sulfamethizol
D013432 Sulfathiazoles Sulfanilamides consisting of a 4-aminobenzenesulfonamido group at the 2-position of 1,3-thiazole. They are often used as ANTI-INFECTIVE AGENTS.

Related Publications

K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
February 1990, Journal of pharmacobio-dynamics,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
February 1990, Journal of pharmacobio-dynamics,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
February 1982, Journal of pharmacokinetics and biopharmaceutics,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
November 1987, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
April 1976, Acta endocrinologica,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
April 1968, The Journal of urology,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
June 1968, Endocrinology,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
January 1964, Acta physiologica Polonica,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
May 1971, Chemical & pharmaceutical bulletin,
K Katayama, and E Tsubota, and M Endoh, and M Kakemi, and T Koizumi
January 1969, Scandinavian journal of clinical and laboratory investigation. Supplementum,
Copied contents to your clipboard!